Safety and Efficacy of the ONCOlytic VIRus Armed for Local Chemotherapy, TG6002/5-FC, in Recurrent Glioblastoma Patients

Trial Profile

Safety and Efficacy of the ONCOlytic VIRus Armed for Local Chemotherapy, TG6002/5-FC, in Recurrent Glioblastoma Patients

Not yet recruiting
Phase of Trial: Phase I/II

Latest Information Update: 29 Sep 2017

At a glance

  • Drugs TG 6002 (Primary) ; Flucytosine
  • Indications Glioblastoma
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms ONCOVIRAC
  • Most Recent Events

    • 29 Sep 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top